Improved incidence of pT0 downstaged surgical specimens in locally advanced rectal cancer (LARC) treated with induction oxaliplatin plus 5-fluorouracil and preoperative chemoradiation

Annals of Oncology

Volumn 17, Issue 7, 2006, Pages 1103-1110

  Calvo, F A ^a   Serrano, F J ^a   Diaz Gonzalez J A ^a   Gomez Espi, M ^a   Lozano, E ^a   Garcia, R ^a   de la Mata, D ^a   Arranz, J A ^a   Garcia Alfonso P ^a   Perez Manga G ^a   Alvarez E ^a  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

Author keywords

Chemoradiation; Downstaging; Neoadjuvant oxaliplatin; Rectal cancer; Tegafur

Indexed keywords

FLUOROURACIL; FOLINIC ACID; OXALIPLATIN; TEGAFUR; ANTINEOPLASTIC AGENT; FOLFOX PROTOCOL; PLATINUM COMPLEX;

ADD ON THERAPY; ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER STAGING; CLINICAL PROTOCOL; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG RESPONSE; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MUCOSAL DISEASE; NEUROTOXICITY; OUTCOME ASSESSMENT; PREOPERATIVE RADIOTHERAPY; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; RADIATION DOSE; RECTUM CANCER; SHORT COURSE THERAPY; SKIN TOXICITY; SURGICAL APPROACH; UROGENITAL TRACT DISEASE; COMPARATIVE STUDY; METHODOLOGY; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PREOPERATIVE CARE; RECTUM TUMOR;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; PREOPERATIVE CARE; RADIOTHERAPY DOSAGE; RECTAL NEOPLASMS; TEGAFUR;

EID: 33745622869     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdl085     Document Type: Article

References (58)

1. Valentini V, Coco C, Picciocchi A et al. Does down-staging predict improved outcome after preoperative chemoradiation for extraperitoneal locally advanced rectal cancer? A long-term analysis of 165 patients. Int J Radiat Oncol Biol Phys 2002; 53: 664-674.
2. Wagman R, Minsky BD, Cohen AM et al. Sphincter preservation with preoperative radiation therapy (RT) and coloanal anastomoses: Long term follow up. Int J Radiat Oncol Biol Phys 1998; 42: 51-57.
3. Janjan NA, Khoo VS, Abbruzzese J et al. Tumor downstaging and sphincter preservation with preoperative chemoradiation in locally advanced rectal cancer: The M.D. Anderson Cancer Center experience. Int J Radiat Oncol Biol Phys 1999; 44: 1027-1038.
4. Bosset JF, Magnin V, Maingon P et al. Preoperative radiochemotherapy in rectal cancer: Long-term results of a phase II trial. Int J Raidat Oncol Biol Phys 2000; 46: 323-327.
5. Chari RS, Tyler DS, Anscher MS et al. Preoperative radiation and chemotherapy in the treatment of adenocarcinoma of the rectum. Ann Surg 1995; 221: 778-786.
6. Grann A, Feng C, Wong D et al. Preoperative combined modality therapy for clinically resectable uT3 rectal adenocarcinoma. Int J Radiat Oncol Biol Phys 2001; 49: 987-995.
7. Stryker SJ, Kiel KD, Rademaker A et al. Preoperative 'chemoradiation' for stages II and III rectal carcinoma. Arch Surg 1996; 131: 514-518.
8. Extra JM, Espie M, Calvo F et al. Phase I study of oxaliplatin in patients with advanced cancer. Cancer Chemother Pharmacol 1990; 25: 299-303.
9. Keam SL, Dunn CJ, Figgitt DP. Oxaliplatin: In operable colorectal cancer. Drugs 2005; 65: 89-96.
10. de Gramont A, Figer A, Seymour M et al. Leucorovin and fluorouracil with or without oxaliplatin as first-line treatment of advanced colorectal cancer. J Clin Oncol 2000; 18: 2938-47.
11. André T, Boni C, Monnedji-Bondiaf L et al. Oxaliplatin, fluorouracil and lencovorin as adjuvant treatment of colon cancer. N Engl J Med 2004; 350: 2343-2351.
12. Calvo FA, Serrano FJ, García-Alfonso P et al. Neoadjuvant oxaliplatin + 5FU followed by chemo-radiation in rectal cancer: Post-resection p stage, pTsize and degree of histological residue. Proc Am Soc Clin Oncol 2003; 1359 (abstr.).
13. Sauer R, Becker H, Hohenberger W et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004; 351: 1731-1740.
14. Bujko K, Nowacki MP, Nasierowska-Guttmejer A et al. Sphincter preservation following preoperative radiotherapy for rectal cancer: report of a randomised trial comparing short-term radiotherapy vs. conventionally fractionated radiochemotherapy. Radiother Oncol 2004; 72: 15-24.
15. Gerard JP, Romesteing P, Bonnetain F et al. Preoperative chemoradiotherapy (CT-RT) improves local control in T3-4 rectal cancer: results of the FFCD 9203 randomized trial. Int J Radiat Oncol Biol Phys 2005; 63 (suppl 1): S2-s3 (abstr. 4).
16. Calvo FA, Gomez-Espi M, Diaz-González JA et al. Pathologic downstaging of T3-4Nx rectal cancer after chemoradiation: 5-fluorouracil vs. tegafur. Int. J Radiat Oncol Biol Phys 2001; 51: 1264-1270.
17. Chau I, Brown G, Cunningham D et al. Neoadjuvant capecitabine and oxaliplatin followed by synchronous chemoradiation and total mesorectal excision in magnetic resonance imaging-defined poor-risk rectal cancer. J Clin Oncol 2006; 24: 668-674.
18. Aschele C, Friso ML, Pucciarelli S et al. A phase I-II study of weekly oxaliplatin, 5-Fluorouracil continuous infusion and preoperative radiotherapy in locally advanced rectal cancer. Ann Oncol 2005; 16: 1140-1146.
19. Machiels JP, Duck L, Honhon B et al. Phase II study of preoperative oxaliplatin, capecitabine and external beam radiotherapy in patients with rectal cancer: The RadiOxCape study. Ann Oncol. 2005; 16: 1898-1905.
20. Calvo FA, Serrano J, Gómez-Espi M et al. Neoadjuvant oxaliplatin (FOLFOX-4) followed by chemoradiation in locally advanced rectal cancer: intermediate results. Proc Am Soc Clin Oncol 2005; 3621 (abstr.).
21. Calvo FA, Gomez-Espi M, Diaz-Gonzalez JA et al. Intraoperative presacral electrón boost following preoperative chemoradiation in T3-4Nx rectal cancer: Initial local effects and clinical outcome análisis. Radiother Oncol 2002; 62: 201-206.
22. LENT SOMA scales for all anatomical sites. Int J Radiat Oncol Biol Phys 1995; 31: 1049-1091.
23. Mandard AM, Dalibard F, Mandard JC et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer 1994; 73: 2680-2686.
24. Valentini V, Coco C, Cellini N et al. Ten years of preoperative chemoradiation for extraperitoneal T3 rectal cancer: Acute toxicity, tumor response, and sphincter preservation in three consecutive studies. Int J Radiat Oncol Biol Phys 2001; 51: 371-83.
25. Janjan NA, Abbruzzese J, Pazdur R et al. Prognostic implications of response to preoperative infusional chemoradiation in locally advanced rectal cancer. Radiother Oncol 1999; 51: 153-160.
26. 3/4 rectal cancer. Int J Radiat Oncol Biol Phys 2005; 61: 1378-1384.
27. Crane CH, Skibber JM, Feig BW et al. Response to preoperative chemoradiation increase the use of sphincter preserving surgery in patients with locally advanced low rectal carcinoma. Cancer 2003; 97: 517-524.
28. Francois Y, Nemoz CJ, Baulieux J et al. Influence of the interval between preoperative radiation therapy and surgery on downstaging and on the rate of sphincter-sparing surgery for rectal cancer: The Lyon R90-01 randomized trial. J Clin Oncol 1999; 17: 2396.
29. Marijnen CAM, Nagtegaal ID, Kranenbarg EK et al. No downstaging after short-term preoperative radiotherapy in rectal cancer patients. J Clin Oncol 2001; 19: 1976-1984.
30. Nagtegaal ID, Marijnen CA, Kranenbarg EK et al. Short-term preoperative radiotherapy interferes with the determination of pathological parameters in rectal cancer. J Pathol 2002; 197: 20-27.
31. Glehen O, Chapet O, Adham M et al. Long-term results of the Lyons R90-01 randomized trail of preoperative radiotherapy and delayed surgery and its effect on sphincter-saving surgery in rectal cancer. Br J Surg 2003; 90: 996-998.
32. Swedish Rectal Cancer Trial. Improved survival with preoperative radiotherapy in respectable rectal cancer. N Engl J Med 1997; 336: 980-987.
33. Berger C, de Muret A, Garaud P et al. Preoperative radiotherapy (RT) for rectal cancer: Predictive factors of tumor downstaging and residual tumor cell density (RTCD). Prognostic implications. Int J Radiat Oncol Biol Phys 1997; 37: 619-627.
34. Kapiteijn E, Marijnen CA, Nagtegaal ID et al. Preoperative readiotherapy combined with total mesorectal escision for resectable rectal cancer. N Engl J Med 2001; 345: 638-646.
35. Gerard JP, Chapet O, Nemoz C et al. Improved sphincter preservation in low rectal cancer with high-dose preoperative radiotherapy: The Lyon R96-02 randomized trial. J Clin Oncol 2004; 22: 2404-2409.
36. Kim JS, Kim JS, Cho MJ et al. Preoperative chemoradiation using oral capecitabine in locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 2002; 54: 403-408.
37. De laTorre A, Ramos S, Valcarcel FJ et al. Phase II study of radiochemotherapy with UFT and low-dose oral leucovorin in patients with unresectable rectal cancer. Int J Radiat Oncol Biol Phys 1999; 45: 629-634.
38. Feliu J. Calvilio J, Escribano A et al. Neoadjuvant therapy of rectal carcinoma with UFT-leucovorin plus radiotherapy. Ann Oncol 2002; 13: 730-736.
39. Fernández-Martos C, Aparicio J, Bosch C et al. Preoperative uracil, tegafur, and concomitant radiotherapy in operable rectal cancer: A phase II multicenter study with 3 years' follow-up. J Clin Oncol 2004; 22: 3016-3022.
40. Nakfoor BM, Willett CG, Shellito PC et al. The impact of 5-fluorouracil and intraoperative electron beam radiation therapy on the outcome of patients with locally advanced primary rectal and rectosigmoid cancer. Ann Surg 1998; 228: 194-200.
41. Vecchio FM, Valentini V, Minsky BD et al. The relationship of pathologic tumor regression grade (TRG) and outcomes after preoperative therapy in rectal cancer. Int J Radiat Oncol Biol Phys 2005; 62: 752-60.
42. Shia J, Guillem JG, Moore HG et al. Patterns of morphologic alteration in residual rectal carcinoma following preoperative chemoradiation and their association with long-term outcome. Am J Surg Pathol 2004; 28: 215-223.
43. Bosset JF, Calais G, Mineur L et al. Enhanced tumoricidal effect of chemotherapy with preoperative radiotherapy for rectal cancer: preliminary results-EORTC 22921. J Clin Oncol 2005; 23: 5620-5627.
44. Minsky B. Oxaliplatin-based combined-modality therapy for rectal cancer. Semin Oncol 2003; 30: 26-33.
45. Gambacorta MA, Valentini V, Coco L et al. Chemoradiation with raltitrexed and oxaliplatin in preoperative treatment of stage II-III resectable rectal cancer: Phase I and II studies. Int J Radiat Oncol Biol Phys 2004; 60: 139-148.
46. Loi S, Ngan SY, Hicks RJ et al. Oxaliplatin combined with infusional 5-fluorouracil and concomitant radiotherapy in inoperable and metastastic rectal cancer: A phase I trial. Br J Cancer 2005; 92: 655-661.
47. Reerink O, Mulder NH, Vershueren RC et al. Addition of oxaliplatin to neo-adjuvant radiochemotherapy for irresectable rectal cancer, a phase I study. Anticancer Res 2005; 25: 629-633.
48. 4 unresectable rectal cancer: A phase II IATTGI study. Int J Radiat Oncol Biol Phys 2002; 54: 397-402.
49. Rödel C, Granbenbauer GG, Papadopoulos T et al. Phase I-II trial capecitabine, oxaliplatin, and radiation for rectal cancer. J Clin Oncol 2003; 21: 3098-3104.
50. Gerard J-P, Chapet O, Nemot Ch et al. Preoperative concurrent chemoradiotherapy in locally advanced rectal cancer with high-dose radiation and oxaliplatin-containing regimen: The Lyon RO-04 phase II trial. J Clin Oncol 2003; 21: 1119-1124.
51. Francois E, Ychou M, Ducreux M et al. Groupe Digestif de la Federation Nationale des Centres de Lutte Contre le Cancer. Combined radiotherapy, 5-fluorouracil continuous infusion and weekly oxaliplatin in advanced rectal cancer: A phase I study. Eur J Cancer. 2005; 41: 2861-2867.
52. Glynne-Jones R, Sebag-Montefiore D, Maughan TS et al. A phase I dose escalation study of continuous oral capecitabine in combination with oxaliplatin and pelvic radiation (XELOX-RT) in patients with locally advanced rectal cancer. Ann Oncol 2006; 17: 50-56.
53. Chau I, Brown G, Cunninghan D et al. Neoadjuvant capecitabine and oxalinplatin followed by synchronous chemoradiation and total mesorectal excision in magnetic resonance imaging-defined post-risk rectal cancer. J Clin Oncol 2006; 24: 668-674.
54. Rödel C, Martus P, Papadoupolos T et al. Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. J Clin Oncol 2005; 23(39): 8688-8696.
55. Calvo FA, Domper M, Matute R et al. 18F-FDG positron emission tomography staging and restaging in rectal cancer treated with preoperative chemoradiation. Int J Radiat Oncol Biol Phys 2004; 58: 528-535.
56. Chessin DB, Akhurst T, Teung H et al. Positron emission tomography during preoperative combined modality therapy for rectal cancer may predict ultimate pathologic response: A prospective analysis. Proc Am Soc Clin Oncol 2005; 3612 (abstr.).
57. 3 rectal cancer patients. Int J Radiat Oncol Biol Phys 2004; 60: 1098-1105.
58. Ghadimi MB, Grade M, Difilippantonio MJ et al. Effectiveness of gene expresion profiling for response prediction of rectal adenocarcinomas to preoperative chemoradiotherapy. J Clin Oncol 2005; 23: 1826-1838.